v3 Template
B
BioVaxys Technology Corp.
Biotechnology / Immunotherapy
Vancouver, BC, Canada
~10 employees
Founded
--
Employees (Est.)
~10
1 leaders known
Total Funding
$28.0M
Funding Rounds
29
Last Funding
2025-11-19
About BioVaxys Technology Corp.
BioVaxys is a biotechnology company focused on revolutionizing immunotherapy by harnessing the power of the immune system to combat diseases. The company aims to advance global health through pioneering immunotherapy solutions, with a focus on developing advanced antigen presentation methods and treatments for oncology, infectious diseases, allergies, autoimmune diseases, and other immune dysfunctions.
Products & Services
DPX™ Delivery Platform:A cutting-edge lipid-based delivery system acquired from IMV Inc., designed to encapsulate bioactive molecules for enhanced and sustained immune responses across various therapeutic domains.
Haptenix(c) - Ovarian Cancer Vaccine (BVX-0918):A Phase I vaccine candidate for Stage III/IV ovarian cancer using haptenization technology to train the immune system to target tumor or viral proteins, incorporating a bi-haptenized tumor cell vaccine and checkpoint inhibitors for potent immune response.
Specialties
Antigen Haptenization Technology
DPX™ Antigen Delivery Platform
Ovarian Cancer Vaccine Development
T-Cell Antigen Discovery
AI in Immunotherapy
Immunological Synergy
Funding History
Debug: View Raw Funding Data
| # | Type | Amount Fields | Date Fields | Investors |
|---|---|---|---|---|
| 1 |
RT: Private Placement T: - FT: Private Placement |
A: 1922985 MR: - FA: $1,922,984.92 FAN: 1922985 |
D: 2025-11-19 FD: 2025-11-19 |
1 investors |
| 2 |
RT: Private Placement T: - FT: Private Placement |
A: 2000000 MR: - FA: $2,000,000 FAN: 2000000 |
D: 2025-11-11 FD: 2025-11-11 |
- |
| 3 |
RT: Private Placement T: - FT: Private Placement |
A: 2000000 MR: - FA: up to $2,000,000 FAN: 2000000 |
D: 2025-10-30 FD: 2025-10-30 |
- |
| 4 |
RT: Convertible Debenture T: - FT: Convertible Debenture |
A: 335670 MR: - FA: 335,670 FAN: 335670 |
D: 2025-09-16 FD: 2025-09-16 |
2 investors |
| 5 |
RT: Convertible Debenture T: - FT: Convertible Debenture |
A: 500000 MR: - FA: up to $500,000 FAN: 500000 |
D: 2025-08-27 FD: 2025-08-27 |
- |
| 6 |
RT: Private Placement T: - FT: Private Placement |
A: 3000000 MR: - FA: Up to $3,000,000 FAN: 3000000 |
D: 2025-07-15 FD: 2025-07-15 |
- |
| 7 |
RT: Private Placement T: - FT: Private Placement |
A: 2000000 MR: - FA: Minimum $2,000,000 to Maximum $3,000,000 FAN: 2000000 |
D: 2025-06-20 FD: 2025-06-20 |
- |
| 8 |
RT: Private Placement T: - FT: Private Placement |
A: 3000000 MR: - FA: up to $3,000,000 FAN: 3000000 |
D: 2025-05-30 FD: 2025-05-30 |
- |
| 9 |
RT: Private Placement T: - FT: Private Placement |
A: 100000 MR: - FA: $100,000 FAN: 100000 |
D: 2025-02-18 FD: 2025-02-18 |
- |
| 10 |
RT: Private Placement T: - FT: Private Placement |
A: 5 MR: - FA: $0.05 per Unit FAN: 5 |
D: 2025-01-23 FD: 2025-01-23 |
- |
| 11 |
RT: Private Placement T: - FT: Private Placement |
A: 537500 MR: - FA: $537,500 FAN: 537500 |
D: 2025-01-10 FD: 2025-01-10 |
- |
| 12 |
RT: Private Placement T: - FT: Private Placement |
A: 175000 MR: - FA: $175,000 FAN: 175000 |
D: 2024-12-18 FD: 2024-12-18 |
- |
| 13 |
RT: Private Placement T: - FT: Private Placement |
A: 110000 MR: - FA: $110,000 FAN: 110000 |
D: 2024-12-13 FD: 2024-12-13 |
- |
| 14 |
RT: Private Placement T: - FT: Private Placement |
A: 1000000 MR: - FA: 1,000,000 FAN: 1000000 |
D: 2024-12-11 FD: 2024-12-11 |
- |
| 15 |
RT: Private Placement T: - FT: Private Placement |
A: 1000000 MR: - FA: CAD$1,000,000 FAN: 1000000 |
D: 2024-11-18 FD: 2024-11-18 |
- |
| 16 |
RT: Private Placement T: - FT: Private Placement |
A: 1240617 MR: - FA: $1,240,617 FAN: 1240617 |
D: 2024-10-25 FD: 2024-10-25 |
- |
| 17 |
RT: Private Placement T: - FT: Private Placement |
A: 225000 MR: - FA: 225,000.00 FAN: 225000 |
D: 2024-10-04 FD: 2024-10-04 |
- |
| 18 |
RT: Private Placement T: - FT: Private Placement |
A: 150000 MR: - FA: $150,000.00 FAN: 150000 |
D: 2024-09-24 FD: 2024-09-24 |
- |
| 19 |
RT: Private Placement T: - FT: Private Placement |
A: 1500000 MR: - FA: $1,500,000 FAN: 1500000 |
D: 2024-09-20 FD: 2024-09-20 |
- |
| 20 |
RT: Private Placement T: - FT: Private Placement |
A: 305000 MR: - FA: $305,000.00 FAN: 305000 |
D: 2024-09-11 FD: 2024-09-11 |
1 investors |
| 21 |
RT: Private Placement T: - FT: Private Placement |
A: 500000 MR: - FA: CAD $500,000 FAN: 500000 |
D: 2024-07-23 FD: 2024-07-23 |
- |
| 22 |
RT: Private Placement T: - FT: Private Placement |
A: 279625 MR: - FA: $279,625.00 FAN: 279625 |
D: 2024-05-10 FD: 2024-05-10 |
- |
| 23 |
RT: Private Placement T: - FT: Private Placement |
A: 333227 MR: - FA: $333,227.31 FAN: 333227 |
D: 2024-05-03 FD: 2024-05-03 |
- |
| 24 |
RT: Private Placement T: - FT: Private Placement |
A: 1000000 MR: - FA: up to CAD$1,000,000 FAN: 1000000 |
D: 2024-03-22 FD: 2024-03-22 |
- |
| 25 |
RT: Private Placement T: - FT: Private Placement |
A: 501500 MR: - FA: $501,500 FAN: 501500 |
D: 2024-02-09 FD: 2024-02-09 |
- |
| 26 |
RT: Private Placement T: - FT: Private Placement |
A: 1103500 MR: - FA: 1,103,500 FAN: 1103500 |
D: 2024-02-09 FD: 2024-02-09 |
- |
| 27 |
RT: non-brokered private placement T: - FT: non-brokered private placement |
A: 501500 MR: - FA: $501,500 FAN: 501500 |
D: 2024-02-09 FD: 2024-02-09 |
- |
| 28 |
RT: Private Placement T: - FT: Private Placement |
A: 1103500 MR: - FA: $1,103,500 FAN: 1103500 |
D: 2024-02-01 FD: 2024-02-01 |
- |
| 29 |
RT: Private Placement T: - FT: Private Placement |
A: 1600000 MR: - FA: CAD$1,600,000 FAN: 1600000 |
D: 2024-01-08 FD: 2024-01-08 |
- |
Private Placement
Latest
2025-11-19
$1.9M
1 investor (Pro only)
Private Placement
2025-11-11
$2.0M
Private Placement
2025-10-30
$2.0M
Growth Metrics
+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active
Mock Up
Team & Leadership
D
Dr. Karl Landsteiner
Nobel laureate
Recent News
BioVaxys Technology Corp. Announces New Product Launch
2 days agoCompany unveils innovative solution to transform the industry, expanding market reach and capabilities...
Read more →Leadership Team Expands with Industry Veteran
1 week agoNew executive brings 20+ years of experience to accelerate growth and strategic initiatives...
Read more →Company Recognized as Industry Leader
2 weeks agoReceives prestigious award for innovation and customer satisfaction in competitive market...
Read more →Mock Up
Key Competitors
C1
Competitor Alpha
Series B · $50M raised
C2
Competitor Beta
Series C · $120M raised
C3
Competitor Gamma
Series A · $25M raised
C4
Competitor Delta
Seed · $10M raised
Mock Up
Company Details
- Website
- biovaxys.com
- Industries
- Biotechnology / Immunotherapy
- Company Size
- ~10 employees (est.)
- Locations
-
Vancouver, BC, Canada
Vancouver, BC
Technology Stack
Discover the backend, frontend, and infrastructure technologies powering this company's products.
Upgrade to Pro